keyword
MENU ▼
Read by QxMD icon Read
search

Pseudoprogression

keyword
https://www.readbyqxmd.com/read/27895919/recurrent-pleural-effusions-and-cardiac-tamponade-as-possible-manifestations-of-pseudoprogression-associated-with-nivolumab-therapy-a-report-of-two-cases
#1
Bhaskar C Kolla, Manish R Patel
BACKGROUND: Checkpoint inhibitors are a class of agents that employ host's adaptive immune defenses in fighting cancer. With many new indications and several ongoing clinical trials in a variety of malignancies, the usage of these agents is set to increase significantly. One of the key challenges patients and physicians face while using these drugs is with the appropriate assessment of response to therapy. CASE PRESENTATION: We are reporting two patients with lung cancer who were treated with nivolumab and experienced rapidly accumulating recurrent pleural effusions requiring multiple thoracenteses (6 and 4 times each for patient 1 and 2 respectively) with in the first few weeks of initiation of therapy and also developed pericardial effusion with cardiac tamponade requiring pericardiocentesis...
2016: Journal for Immunotherapy of Cancer
https://www.readbyqxmd.com/read/27889021/neuroimaging-of-peptide-based-vaccine-therapy-in-pediatric-brain-tumors-initial-experience
#2
REVIEW
Andre D Furtado, Rafael Ceschin, Stefan Blüml, Gary Mason, Regina I Jakacki, Hideho Okada, Ian F Pollack, Ashok Panigrahy
The potential benefits of peptide-based immunotherapy for pediatric brain tumors are under investigation. Treatment-related heterogeneity has resulted in radiographic challenges, including pseudoprogression. Conventional MR imaging has limitations in assessment of different forms of treatment-related heterogeneity, particularly regarding distinguishing true tumor progression from efficacious treatment responses. Advanced neuroimaging techniques, including diffusion magnetic resonance (MR), perfusion MR, and MR spectroscopy, may add value in the assessment of treatment-related heterogeneity...
February 2017: Neuroimaging Clinics of North America
https://www.readbyqxmd.com/read/27885955/editorial-vestibular-schwannoma-radiosurgery-progression-or-pseudoprogression
#3
Jean Régis, Christine Delsanti, Pierre-Hugues Roche
No abstract text is available yet for this article.
November 25, 2016: Journal of Neurosurgery
https://www.readbyqxmd.com/read/27873302/ultrasonographic-findings-can-identify-pseudoprogression-under-nivolumab-therapy
#4
K Imafuku, H Hata, S Kitamura, T Yanagi, H Shimizu
'Pseudoprogression' is often seen in patients with melanomas who are treated with immune-checkpoint inhibitors such as nivolumab or ipilimumab. We sometimes evaluate metastatic lesions by imaging tests such as CT or PET-CT. 'Pseudoprogression' usually occurs upon the initial administration, which may make it difficult for the physician to determine the disease condition. In our two cases of metastatic melanoma treated with nivolumab (anti-PD-1 antibody), we examined the ultrasonography (US) of target lesions that could be accessed from the body surface, such as those of the regional lymph node or subcutaneous metastasis...
November 22, 2016: British Journal of Dermatology
https://www.readbyqxmd.com/read/27864299/challenges-in-the-use-of-immunotherapy-in-metastatic-melanoma
#5
Ashley Tran, Shayna Sarosiek, Naomi Y Ko
A 65-year-old man with metastatic melanoma was started on immunotherapy, switched to alternative targeted therapy and developed disseminated intravascular coagulation. This case underscores the complexity of interpreting and managing side effects of novel therapies in cancer care, identification of progression versus pseudoprogression and challenges in sequencing treatments in metastatic melanoma.
November 18, 2016: BMJ Case Reports
https://www.readbyqxmd.com/read/27822695/the-treatment-of-melanoma-brain-metastases
#6
REVIEW
Nour Kibbi, Harriet Kluger
Melanoma is the malignancy with the highest rate of dissemination to the central nervous system once it metastasizes. Until recently, the prognosis of patients with melanoma brain metastases (MBM) was poor. In recent years, however, the prognosis has improved due to high-resolution imaging that facilitates early detection of small asymptomatic brain metastases and early intervention with local modalities such as stereotactic radiosurgery. More recently, a number of systemic therapies have been approved by the Food and Drug Administration for metastatic melanoma, resulting in improved survival for many MBM patients...
December 2016: Current Oncology Reports
https://www.readbyqxmd.com/read/27806598/stratification-of-pseudoprogression-and-true-progression-of-glioblastoma-multiform-based-on-longitudinal-diffusion-tensor-imaging-without-segmentation
#7
Xiaohua Qian, Hua Tan, Jian Zhang, Weilin Zhao, Michael D Chan, Xiaobo Zhou
PURPOSE: Pseudoprogression (PsP) can mimic true tumor progression (TTP) on magnetic resonance imaging in patients with glioblastoma multiform (GBM). The phenotypical similarity between PsP and TTP makes it a challenging task for physicians to distinguish these entities. So far, no approved biomarkers or computer-aided diagnosis systems have been used clinically for this purpose. METHODS: To address this challenge, the authors developed an objective classification system for PsP and TTP based on longitudinal diffusion tensor imaging...
November 2016: Medical Physics
https://www.readbyqxmd.com/read/27788956/a-study-of-pseudoprogression-after-spine-stereotactic-body-radiation-therapy
#8
Houda Bahig, Dany Simard, Laurent Létourneau, Philip Wong, David Roberge, Edith Filion, David Donath, Arjun Sahgal, Laura Masucci
PURPOSE: To determine the incidence of pseudoprogression (PP) after spine stereotactic body radiation therapy based on a detailed and quantitative assessment of magnetic resonance imaging (MRI) morphologic tumor alterations, and to identify predictive factors distinguishing PP from local recurrence (LR). METHODS AND MATERIALS: A retrospective analysis of 35 patients with 49 spinal segments treated with spine stereotactic body radiation therapy, from 2009 to 2014, was conducted...
November 15, 2016: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/27776933/amidst-the-excitement-a-cautionary-tale-of-immunotherapy-pseudoprogression-and-head-and-neck-squamous-cell-carcinoma
#9
EDITORIAL
Shrujal S Baxi, Lara A Dunn, Barbara A Burtness
No abstract text is available yet for this article.
November 2016: Oral Oncology
https://www.readbyqxmd.com/read/27764705/idh-mutation-and-mgmt-promoter-methylation-are-associated-with-the-pseudoprogression-and-improved-prognosis-of-glioblastoma-multiforme-patients-who-have-undergone-concurrent-and-adjuvant-temozolomide-based-chemoradiotherapy
#10
Hailong Li, Jiye Li, Gang Cheng, Jianning Zhang, Xuezhen Li
PURPOSE: This study aimed to investigate the potential association between IDH mutation and O(6)-methyl-guanine methyl transferase (MGMT) gene promoter methylation and pseudoprogression disease (psPD) in glioblastoma multiforme (GBM) patients after concurrent temozolomide (TMZ)-based chemoradiotherapy. METHODS: A total of 157 GBM patients who received concurrent TMZ-based chemoradiotherapy were included in this retrospective study. The association between psPD and a number of demographic and genetic factors, including IDH mutation and MGMT promoter methylation, were analyzed based on logistic regression, Cox regression, and multivariate analysis...
October 12, 2016: Clinical Neurology and Neurosurgery
https://www.readbyqxmd.com/read/27742111/response-assessment-in-neuro-oncology-criteria-and-clinical-endpoints
#11
Raymond Y Huang, Patrick Y Wen
The Response Assessment in Neuro-Oncology (RANO) Working Group is an international multidisciplinary group whose goal is to improve response criteria and define endpoints for neuro-oncology trials. The RANO criteria for high-grade gliomas attempt to address the issues of pseudoprogression, pseudoresponse, and nonenhancing tumor progression. Incorporation of advanced MR imaging may eventually help improve the ability of these criteria to define enhancing and nonenhancing disease better. The RANO group has also developed criteria for neurologic response and evaluation of patients receiving immunologic therapies...
November 2016: Magnetic Resonance Imaging Clinics of North America
https://www.readbyqxmd.com/read/27704386/molecular-and-histologic-characteristics-of-pseudoprogression-in-diffuse-gliomas
#12
Andrew L Lin, Michael White, Michelle M Miller-Thomas, Robert S Fulton, Christina I Tsien, Keith M Rich, Robert E Schmidt, David D Tran, Sonika Dahiya
During the 6 month period following chemoradiotherapy, gliomas frequently develop new areas of contrast enhancement, which are due to treatment effect rather than tumor progression. We sought to characterize this phenomenon in oligodendrogliomas (OG) and mixed oligoastrocytomas (MOA). We reviewed the imaging findings from 143 patients with a WHO grade II or III OG or MOA for evidence of pseudoprogression (PsP) or early tumor progression. We characterized these cases for 1p/19q codeletions by FISH, IDH1 R132H mutation by immunohistochemistry, and TP53, ATRX, and EGFR mutations by next generation sequencing...
October 4, 2016: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/27673782/pseudoprogression-of-glioblastoma-multiforme-after-chemoradiation-therapy-diagnosis-by-11c-methionine-positron-emission-tomography-pet
#13
M Matsuo, H Tanaka, T Yamaguchi, H Nishibori, S Ogawa
No abstract text is available yet for this article.
October 1, 2016: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/27663515/immune-biomarkers-of-treatment-failure-for-a-patient-on-a-phase-i-clinical-trial-of-pembrolizumab-plus-radiotherapy
#14
Gregory S Alexander, Joshua D Palmer, Madalina Tuluc, Jianqing Lin, Adam P Dicker, Voichita Bar-Ad, Larry A Harshyne, Jennifer Louie, Colette M Shaw, D Craig Hooper, Bo Lu
BACKGROUND: Pembrolizumab is a monoclonal antibody that is designed against programmed cell death protein 1 (PD-1). Pembrolizumab and other immunocheckpoint-blocking monoclonal antibodies work by modulating a patient's own immune system to increase anti-tumor activity. While immunocheckpoint blockade has shown promising results, only 20-40 % of patients experience objective clinical benefit. Differences in individual tumor biology and the presence multiple immune checkpoints present a challenge for treatment...
September 23, 2016: Journal of Hematology & Oncology
https://www.readbyqxmd.com/read/27624914/antigen-specific-immunoreactivity-and-clinical-outcome-following-vaccination-with-glioma-associated-antigen-peptides-in-children-with-recurrent-high-grade-gliomas-results-of-a-pilot-study
#15
Ian F Pollack, Regina I Jakacki, Lisa H Butterfield, Ronald L Hamilton, Ashok Panigrahy, Daniel P Normolle, Angela K Connelly, Sharon Dibridge, Gary Mason, Theresa L Whiteside, Hideho Okada
Recurrent high-grade gliomas (HGGs) of childhood have an exceedingly poor prognosis with current therapies. Accordingly, new treatment approaches are needed. We initiated a pilot trial of vaccinations with peptide epitopes derived from glioma-associated antigens (GAAs) overexpressed in these tumors in HLA-A2+ children with recurrent HGG that had progressed after prior treatments. Peptide epitopes for three GAAs (EphA2, IL13Rα2, survivin), emulsified in Montanide-ISA-51, were administered subcutaneously adjacent to intramuscular injections of poly-ICLC every 3 weeks for 8 courses, followed by booster vaccines every 6 weeks...
September 13, 2016: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/27609621/preradiotherapy-mr-imaging-a-prospective-pilot-study-of-the-usefulness-of-performing-an-mr-examination-shortly-before-radiation-therapy-in-patients-with-glioblastoma
#16
C Majós, M Cos, S Castañer, A Pons, M Gil, A Fernández-Coello, M Macià, J Bruna, C Aguilera
BACKGROUND AND PURPOSE: Current protocols in patients with glioblastoma include performing an MR examination shortly after surgery and then 2-6 weeks after ending concomitant chemoradiotherapy. The assessment of this first postradiotherapy examination is challenging because the pseudoprogression phenomenon may appear. The aim of this study was to explore if performing an MR examination shortly before radiation therapy (preradiotherapy MR imaging) could improve the radiologic assessment of patients with glioblastoma...
September 8, 2016: AJNR. American Journal of Neuroradiology
https://www.readbyqxmd.com/read/27536188/high-grade-glioma-management-and-response-assessment-recent-advances-and-current-challenges
#17
REVIEW
M N Khan, A M Sharma, M Pitz, S K Loewen, H Quon, A Poulin, M Essig
The management of high-grade gliomas (hggs) is complex and ever-evolving. The standard of care for the treatment of hggs consists of surgery, chemotherapy, and radiotherapy. However, treatment options are influenced by multiple factors such as patient age and performance status, extent of tumour resection, biomarker profile, and tumour histology and grade. Follow-up cranial magnetic resonance imaging (mri) to differentiate treatment response from treatment effect can be challenging and affects clinical decision-making...
August 2016: Current Oncology
https://www.readbyqxmd.com/read/27535746/serial-analysis-of-3d-h-1-mrsi-for-patients-with-newly-diagnosed-gbm-treated-with-combination-therapy-that-includes-bevacizumab
#18
Sarah J Nelson, Yan Li, Janine M Lupo, Marram Olson, Jason C Crane, Annette Molinaro, Ritu Roy, Jennifer Clarke, Nicholas Butowski, Michael Prados, Soonmee Cha, Susan M Chang
Interpretation of changes in the T1- and T2-weighted MR images from patients with newly diagnosed glioblastoma (GBM) treated with standard of care in conjunction with anti-angiogenic agents is complicated by pseudoprogression and pseudoresponse. The hypothesis being tested in this study was that 3D H-1 magnetic resonance spectroscopic imaging (MRSI) provides estimates of levels of choline, creatine, N-acetylaspartate (NAA), lactate and lipid that change in response to treatment and that metrics describing these characteristics are associated with survival...
October 2016: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/27515827/evaluation-of-pseudoprogression-rates-and-tumor-progression-patterns-in-a-phase-iii-trial-of-bevacizumab-plus-radiotherapy-temozolomide-for-newly-diagnosed-glioblastoma
#19
Wolfgang Wick, Olivier L Chinot, Martin Bendszus, Warren Mason, Roger Henriksson, Frank Saran, Ryo Nishikawa, Cedric Revil, Yannick Kerloeguen, Timothy Cloughesy
BACKGROUND: Evaluation of glioblastoma disease status may be complicated by treatment-induced changes and discordance between enhancing and nonenhancing MRI. Exploratory analyses are presented (prospectively assessed pseudoprogression and therapy-related tumor pattern changes) from the AVAglio trial (bevacizumab or placebo plus radiotherapy/temozolomide for newly diagnosed glioblastoma). METHODS: MRI was done every 8 weeks (beginning 4 wk after chemoradiotherapy) using prespecified and standardized T1 and T2 protocols...
October 2016: Neuro-oncology
https://www.readbyqxmd.com/read/27469356/epileptic-activity-increases-cerebral-amino-acid-transport-assessed-by-18f-fluoroethyl-l-tyrosine-amino-acid-pet-a-potential-brain-tumor-mimic
#20
Markus Hutterer, Yvonne Ebner, Markus J Riemenschneider, Antje Willuweit, Mark McCoy, Barbara Egger, Michael Schröder, Christina Wendl, Dirk Hellwig, Jirka Grosse, Karin Menhart, Martin Proescholdt, Brita Fritsch, Horst Urbach, Günther Stockhammer, Ulrich Roelcke, Norbert Galldiks, Philipp Meyer, Karl-Josef Langen, Peter Hau, Eugen Trinka
: O-(2-[(18)F]-fluoroethyl)-L-tyrosine positron emission tomography ((18)F-FET PET) is a well-established method increasingly used for diagnosis, treatment planning and monitoring in gliomas. Epileptic activity, frequently occurring in glioma patients, can influence MRI findings. Whether seizures also affect (18)F-FET PET imaging is currently unknown. The aim of this retrospective analysis was to investigate the brain amino acid metabolism during epileptic seizures by (18)F-FET PET and to elucidate the pathophysiological background...
July 28, 2016: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
keyword
keyword
12545
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"